• Recruiting

NCT05347485: Phase 2: A Study of JNJ-68284528 Out-of-Specification (OOS) for Commercial Release

Updated: Sep 8


NCT05347485: Phase 2: A Study of JNJ-68284528 Out-of-Specification (OOS) for Commercial Release in Participants With Multiple Myeloma

cilta-cel cart myeloma janssen

The purpose of this study is to evaluate the efficacy and safety of cilta-cel out-of-specification (OOS).


Sponsor

Janssen Scientific Affairs, LLC

 

ClinicalTrials.gov Identifier: NCT05347485


Official Title: A Safety and Efficacy Study of JNJ-68284528 (Ciltacabtagene Autoleucel) Out-of-Specification (OOS) for Commercial Release in Patients With Multiple Myeloma

First Posted: April 26, 2022


Click here for details on ClinicalTrials.gov


A Study of JNJ-68284528 Out‐of‐Specification (OOS) for Commercial Release in Participants with Multiple Myeloma | Global Trial Finder (janssen.com)

 

CART - BCMA : National Cancer Institute

JNJ-68284528 - ciltacabtagene autoleucel


CART

JNJ-68284528

Ciltacabtagene Autoleucel

 

Drug: Cilta-cel

Drug: Lymphodepleting Therapy (Cyclophosphamide and Fludarabine)

 

Locations

United States, California

United States, Colorado

United States, Florida

United States, Georgia

United States, Illinois

United States, Kansas

United States, Massachusetts

United States, Michigan

United States, Minnesota

United States, Missouri

United States, New Jersey

United States, New York

United States, North Carolina

United States, Pennsylvania

United States, Texas

United States, Washington

United States, Wisconsin

Posts Archive